U.S. District Chief Judge Joseph Farnan Jr.’s decision to invalidate a patent on a long-lasting narcotic may ultimately cost drugmaker Purdue Frederick Co. as much as $600 million in worldwide sales, experts say.

In a decision released May 7, Farnan in Wilmington concluded Purdue Frederick’s patent on treating pain with a slow-release oral dose does not meet legal requirements in its written description to be valid.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]